Auris Medical Provides Business Update and Reports Second

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Auris Medical Provides Business Update and Reports Second Quarter 2016 Financial Results
  • TACTT2 trial with Keyzilen TM for acute inner ear tinnitus did not meet efficacy endpoints
  • Top-line results from TACTT3 trial with Keyzilen TM expected in the fourth quarter of 2016
  • AM-111 Phase 3 program for acute inner ear hearing loss is ongoing
  • Conference call today at 8 am Eastern Time

ZUG, Switzerland, Aug. 18, 2016 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today provided a business update and announced financial results for the second quarter ended June 30, 2016.

"As stated earlier today, we are disappointed with the top-line results from the TACTT2 trial with Keyzilen TM for acute inner ear tinnitus and we continue to assess the full dataset. We plan to complete this analysis and meet with the regulatory agencies prior to the TACTT3 readout, which is expected in the fourth quarter," commented Thomas Meyer, Auris Medical's founder, Chairman and Chief Executive Officer. "Apart from this, we are pleased with the progress of our second Phase 3 asset, AM-111 for the treatment of acute sensorineural hearing loss, which is progressing with enrollment into the HEALOS and ASSENT trials. Furthermore, we have appointed Thomas Jung to our management team as Chief Development Officer to support our clinical, preclinical and pharmaceutical development activities."

Development Program Updates

Keyzilen TM (AM-101) for Acute Inner Ear Tinnitus

  • Announced top-line results from the Phase 3 TACTT2 trial in acute inner ear tinnitus. The TACTT2 trial did not meet the two co-primary efficacy endpoints of statistically significant changes in tinnitus loudness and tinnitus burden compared to placebo. Data from the TACTT2 trial support the positive safety profile established in previous studies.  
  • Completed enrollment of the Phase 3 TACTT3 trial with more than 300 patients during the acute tinnitus stage (Stratum A) and approximately 330 patients during the post-acute tinnitus stage (Stratum B). The trial, which is being conducted in Europe, is a randomized, double-blind, placebo-controlled trial in acute and post-acute inner ear tinnitus following traumatic cochlear injury or otitis media. The primary endpoint is the change in tinnitus loudness from baseline to Day 84; the change in the TFI is the key secondary efficacy outcome. Top-line results from this trial are expected in the fourth quarter of 2016.  
  • Received fast track designation from the FDA for Keyzilen TM in acute peripheral (inner ear) tinnitus following traumatic cochlear injury or otitis media in adults, highlighting the seriousness of the condition as well as the unmet medical need.

AM-111 for Acute Inner Ear Hearing Loss

  • Progressed with enrollment in the Phase 3 HEALOS trial, which is being conducted in several European and Asian countries. The trial aims to enroll approximately 255 patients with severe to profound idiopathic sudden sensorineural hearing loss. Top-line results from this trial are expected in the second half of 2017.  
  • Initiated the Phase 3 ASSENT trial, which is being conducted in the US, Canada and South Korea. The trial aims to enroll approximately 300 patients with severe to profound idiopathic sudden sensorineural hearing loss. Top-line results from this trial are expected in the first half of 2018.

              Other Developments

  • Appointed Thomas Jung, MD, PhD, as Chief Development Officer. In this newly created position, Dr. Jung will lead the Company's clinical, preclinical and pharmaceutical development activities. He will join Auris Medical in September. Dr. Jung previously served as the Chief Medical Officer at Delenex Therapeutics AG and spent 13 years at Novartis, most recently as Head, Translational Medicine for the European Union.  
  • Received $12.5 million in financing from a loan facility agreement with Hercules Capital, Inc.

Second Quarter 2016 Financial Results

  • Cash and cash equivalents at June 30, 2016, totaled CHF 32.8 million, which does not include the $12.5 million received in July 2016 as part of the loan facility.  
  • Total operating expenses for the second quarter of 2016 were CHF 9.0 million compared to CHF 9.7 million for the second quarter of 2015.  
  • Research and development expenses for the second quarter of 2016 were CHF 7.3 million compared to CHF 8.8 million for the second quarter of 2015.  
  • General and administrative expenses for the second quarter of 2016 were CHF 1.7 million compared to CHF 0.9 million for the second quarter of 2015.  
  • Net loss for the second quarter of 2016 was CHF 8.43 million, or CHF 0.25 per share, compared to CHF 10.96 million, or CHF 0.34 per share, for the second quarter of 2015. The net loss includes a net unrealized foreign currency exchange gain of CHF 0.6 million in the second quarter of 2016 compared to a foreign currency exchange loss of CHF 1.2 million in the second quarter of 2015.

The Company continues to expect that its operating expenses in 2016 will be in the range of CHF 33.0 to 38.0 million and believes that existing cash and cash equivalents, including the $12.5 million loan, will enable the funding of operations until year-end 2017.

Today's Conference Call & Webcast Information

Auris Medical will host a conference call and webcast to discuss the top-line results from the TACTT2 trial, the second quarter 2016 financial results and to provide a general business update today, August 18, 2016, at 8:00 am Eastern Time (2:00 pm Central European Time). To participate in this conference call, dial 1-877-280-3459 (USA) or +1-646-254-3387 (International), and enter passcode 9451099. A live webcast of the conference call will be available in the Investor Relations section of the Auris Medical website at www.aurismedical.com and a replay of the conference call will be available following the live call.

About Auris Medical

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the Phase 3 development of treatments for acute inner ear tinnitus (Keyzilen TM ; AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."

Forward-looking Statements

This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or Auris Medical's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the timing and conduct of clinical trials of Auris Medical's product candidates, the clinical utility of Auris Medical's product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical's intellectual property position and Auris Medical's financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical's capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Auris Medical's Annual Report on Form 20-F and future filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Company contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 13 50, investors@aurismedical.com

Media contact: David Schull, Russo Partners, 1-858-717-2310, david.schull@russopartnersllc.com

Auris Medical Holding AG Condensed Consolidated Interim Statement of Loss and Other Comprehensive Loss (unaudited) (in CHF)

    THREE MONTHS ENDED JUNE 30   SIX MONTHS ENDED JUNE 30
    2016   2015   2016   2015
Research and development     -7,278,563   -8,750,891   -13,418,738   -14,980,787
General and administrative   -1,725,114   -980,187   -2,947,146   -1,910,106
Operating loss   -9,003,677   -9,731,078   -16,365,884   -16,890,893
Interest income   15,281   5,210   26,166   10,268
Interest expense   -2,514   -2,540   -5,259   -4,604
Foreign currency exchange gain/(loss), net   558,908   -1,230,018   -985,937   -2,125,308
Loss before tax   -8,432,002   -10,958,426   -17,330,914   -19,010,537
Income tax expense   -   -   -   -
Net loss attributable to owners of the Company   -8,432,002   -10,958,426   -17,330,914   -19,010,537
Other comprehensive loss:                
Items that will never be reclassified to                
profit or loss                
Remeasurements of defined benefit liability, net of taxes of CHF 0   -347,398   -306   -607,867   -229,170
Items that are or may be reclassified to                
profit or loss                
Foreign currency translation differences,                
net of taxes of CHF 0   -15,856   38,501   25,964   56,863
Other comprehensive (loss)/income,   -363,254   38,195   -581,903   -172,307
net of taxes of CHF 0        
Total comprehensive loss attributable to owners of the Company   -8,795,256   -10,920,231   -17,912,817   -19,182,844
  Basic and diluted loss per share   -0.25   -0.34   -0.50   -0.62

Auris Medical Holding AG Condensed Consolidated Interim Statement of Financial Position (unaudited) (in CHF)

    JUNE 30, 2016   DECEMBER 31, 2015
     
ASSETS        
Non-current assets        
Property and equipment   185,324   222,570
Intangible assets   1,482,520   1,482,520
Other non-current receivables   38,066   38,066
Total non-current assets   1,705,910   1,743,156
         
Current assets        
Other receivables   1,387,380   650,716
Prepayments   17,789   181,044
Cash and cash equivalents   32,780,841   50,237,300
Total current assets   34,186,010   51,069,060
         
Total assets   35,891,920   52,812,216
         
         
Equity        
Share capital   13,731,881   13,721,556
Share premium   112,838,815   112,662,910
Foreign currency translation reserve   -37,858   -63,821
Accumulated deficit   -99,440,625   -81,578,733
Total shareholders' equity attributable to owners of the Company   27,092,213   44,741,912
         
Non-current liabilities        
Employee benefits   2,245,431   1,575,833
Deferred tax liabilities   327,637   327,637
Total non-current liabilities   2,573,068   1,903,470
         
Current liabilities        
Trade and other payables   660,341   1,205,522
Accrued expenses   5,566,298   4,961,312
Total current liabilities   6,226,639   6,166,834
         
Total liabilities   8,799,707   8,070,304
         
Total equity and liabilities   35,891,920   52,812,216

HUG#2035834

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 119

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Alley Cat Allies Pushes for Humane Cat Conservation Bill

Updated Category News Views 70

Time to Rethink Conservation: Save the Cats If you’re tuned into the chatter buzzing around the Cayman Islands, you know the clocks are ticking for a decision that could change the approach to handling community cats. Alley Cat Allies is waving the flag, urging the Cayman Islands Parliament to pass a bill that abandons the archaic practice of culling cats by shooting...

Continue Reading
Blueprint Strengthens Team with New Capital Markets Director

Updated Category News Views 75

Blueprint Bolsters Its Ranks Hiring Caitlin Novak as Managing Director marks a pivotal step for Blueprint Healthcare Real Estate Advisors. They aren't just swapping pawns; they're making a statement, beefing up their capital markets strategy with a heavy hitter seasoned in steering around fiscal pitfalls. Novak isn’t some rookie wet behind the ears—she's clocked more...

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 133

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
SahajMobile's $25M Boost: Impact on Bangladesh Market

Updated Category News Views 128

Untapped Digital Frontier in Bangladesh There's an undeniable buzz around SahajMobile's recent $25 million credit facility, and it's one worth dissecting. This shot of capital, lined up with ALMA as part of SahajMobile’s Series A gamble, is setting the stage for a real shuffle in Bangladesh's digital landscape. Plugging into a Market Gap Ever since it hit the ground...

Continue Reading
A&G Management's Bold New Era with WPM Partnership

Updated Category News Views 152

Shaking Up Baltimore's Real Estate Scene Swapping up management partners can be a dicey game, but A&G Management seems to be pulling it off without a hitch. As of January 4, 2027, WPM Real Estate Management will take over the reins for more than 3,000 apartment homes scattered across Anne Arundel, Howard, and Baltimore counties. A new set of hands is stepping in for...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 118

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading
SANY's Bold AI Showdown at bauma CHINA 2026

Updated Category News Views 60

SANY's Future Vision: AI Agents and Robotic Machinery The construction machinery game is about to get a whole lot smarter, if SANY has anything to say about it. They're rolling out their biggest show ever at bauma CHINA 2026, and the headline act? A fresh breed of AI agents and robotic machinery that promises to revolutionize the industry. Marking its 40-year legacy, SANY...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 158

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
First Time Homebuyer Tips for Southern Maryland Success

Updated Category News Views 94

Shaking Up First-Time Homebuyer Assumptions Ever hear that age-old nonsense about needing a fat stack of cash as a down payment before you can snag your first home? Yeah, turns out that's about as outdated as a rotary phone. Robin Cavallaro from RE/MAX Realty Group in Annapolis is setting the record straight for first-time buyers in Southern Maryland. Down Payment Myths...

Continue Reading

Top 5 Most Recently Viewed Articles

Aardvark Therapeutics Advances Obesity Treatment Research

Updated Category News Views 140

Aardvark Therapeutics Unveils New Data on Obesity Treatments Aardvark Therapeutics, Inc. (AARD) recently showcased significant insights from its metabolic obesity pipeline at the latest conference dedicated to obesity, titled ObesityWeek 2025. This presentation highlighted the promising preclinical results of their innovative drug, ARD-201, which aims to enhance glucose...

Continue Reading
ITC Holdings Corp. Welcomes Carlo Capra as New VP of Engineering

Updated Category News Views 189

ITC Holdings Corp. Names Carlo Capra as Vice President of Engineering ITC Holdings Corp. has recently announced an important leadership change with the appointment of Carlo Capra as the company's new Vice President of Engineering, effective February 26, 2026. This move follows the retirement of Joe Bennett, who has played a vital role in ITC's development during his...

Continue Reading
Safeguarding Your Rights as a WEBTOON Entertainment Shareholder

Updated Category News Views 246

Understanding Your Rights as a WEBTOON Entertainment Shareholder Shareholders are urged to take action promptly, as the time to enforce your rights may be limited. Halper Sadeh LLC, an advocacy law firm focused on shareholder rights, is exploring claims regarding potential breaches of fiduciary duties by some officers and directors of WEBTOON Entertainment Inc. (NASDAQ:...

Continue Reading
TransDigm Group Delivers Strong First Quarter Performance

Updated Category News Views 124

TransDigm Group Reports First Quarter Results for Fiscal 2025 TransDigm Group Incorporated (NYSE: TDG), recognized as a leading designer, producer, and supplier of highly engineered aircraft components, recently announced their financial outcomes for the first quarter of fiscal 2025. First Quarter Financial Highlights In this first quarter, TransDigm Group achieved...

Continue Reading
Understanding Market Movements and TEM Stock Trends

Updated Category News Views 153

Market Activity Around Tempus AI In recent trading sessions, significant bearish sentiment has emerged around Tempus AI (TEM). This shift appears to be fueled by large investors taking notable positions that raise eyebrows among retail traders seeking insights on potential market movements. The Current Trading Landscape Today, we observed unusual activity in the options...

Continue Reading